What each tablet is
Foundayo is orforglipron, FDA-approved 1 April 2026, a daily oral without food or water timing restrictions. Wegovy pill is oral semaglutide, launched January 2026, taken on an empty stomach with a small amount of water and a wait before food, drink, or other orals.
They are not the same molecule. They are not interchangeable at the pharmacy. A clinician picks one.
Bridge treats the copay the same
If the demonstration PA is approved, each is $50 per month through 31 December 2027. That $50 does not count toward TrOOP. Extra Help does not apply. A prior 2026 Part D GLP-1 generally blocks both.
Cash does not treat them the same
Foundayo lowest-dose cash via LillyDirect is often about $149. Wegovy pill 4 mg cash is $149 through 31 August 2026, then $199; maintenance is often $299 on NovoCare.
Commercial-plus-card can be about $25 for either when the plan covers the drug and the member is commercial. Government coverage excludes the card.
The practical fork
If the person cannot protect an empty-stomach window or already has a crowded morning pillbox, Foundayo is the oral that fits the day. If they can keep the window and the clinician prefers semaglutide, the Wegovy pill remains a Bridge option.
Side effects, titration, and labeled indications are clinical. This comparison is paths and routines.
What VitalHound will ask
Preferred product, whether the empty-stomach window is workable, and the morning-med list. The checklist then names one oral so the PA is not written 'GLP-1 tablet.'
Questions
Can I switch between them month to month on Bridge?
Which is 'stronger'?
Is a $449 telehealth bundle cheaper for either?
What if the Rx is for type 2 diabetes?
Not sure this applies to you?
Answer a few questions and see your own numbers.
Free to see which path is likely cheapest for your coverage.
Check my options